Whole genome sequencing and admixture analyses of neuropathologic traits in diverse cohorts in USA and brazil
Active Project Grant Awarded Last action
- Award ID
- R01AG075927
- Recipient
-
Rush University Medical Center UEI C155UU2TXCP3
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $18,782,613
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 65% complete
- Place of performance
- Chicago, IL 60612, USA
Award details come from USAspending.gov.
Description
- Abstract
- Identifying molecular drivers of alzheimer's disease and related dementias (ad/ADRD) pathologies is an urgent public health priority. This is especially important in persons of african ancestry. The overall goal of the proposed study is to identify genes and proteins that drive common ad/ADRD pathologic traits. We previously used multi-level omics to identify molecular drivers of ad/ADRD pathologic traits in non-latinx whites. The proposed study, submitted in response to not-AG-18-053 will extend this work by leveraging an unique, ongoing, diverse study being conducted in SAO paulo, brazil, called "pathology, alzheimer´S and related dementias study" (PARDOS) and five other diverse cohorts in the USA, with whole genome sequencing (WGS) on more than 1350 diverse autopsied participants. PARDOS is prospectively generating neuropathologic and clinical ad/ADRD traits, and DNA on admixed brazilians of european and african, and to a lesser extent native brazilian ancestry. The proposal has the following aims. Aim 1 will generate WGS on an additional 7650 persons in collaboration with the alzheimer's disease sequencing project (ADSP). Aim 2 will perform deep admixture mapping of known snps for alzheimer's dementia, to determine their associations with ad/ADRD neuropathologic phenotypes in 6500 admixed brazilian brains followed generalization to 300 diverse brains from the USA, and discovery analyses for 5500 brazilians followed by generalization to 2000 diverse samples in the USA. Aim 3 will computationally determine telomere length (TL) and examine their association with ad/ADRD clinical and pathologic traits. An exploratory analysis will examine for rare variant associations with ad/ADRD neuropathologic traits. Aim 5 will examine the association of mitochondrial DNA to ad/ADRD traits.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,226,060 | |
| Amendment | $2,290,856 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $679,014 | |
| Amendment | $679,014 | |
| Amendment | $3,251,970 | |
| Amendment | $3,251,970 | |
| Amendment | $0 | |
| Amendment | $3,731,942 | |
| Original award | $3,671,787 |
Show all 13
Subawards
Quick answers
Who received award R01AG075927?
R01AG075927 was awarded to Rush University Medical Center by National Institute on Aging (National Institutes of Health) on August 15, 2023.
How much is award R01AG075927 worth?
$18,782,613 has been obligated on R01AG075927.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award